NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
Clinical Trials
55 trialsNCT05843253 2026-03-04
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT00080938 2023-06-29
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00582075 2023-03-27
RAD0102
University of Alabama at Birmingham
Phase 2 Completed
NCT02343549 2022-11-03
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00049361 2021-09-09
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
Wake Forest University Health Sciences
Phase 2 Completed
NCT01740258 2021-01-26
BBP
Duke University
Phase 2 Completed
NCT00012116 2020-08-03
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT01402063 2020-02-17
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Brown University
Phase 2 Completed
NCT00826241 2019-03-22
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01164189 2019-02-28
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00400816 2018-09-18
Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
The Cleveland Clinic
Phase 2 Completed
NCT00433381 2018-09-17
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01868906 2018-08-24
FMISOPETSCS
Dr. Negrin University Hospital
Phase 2 Terminated
NCT00003176 2018-06-27
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00006358 2018-06-26
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00617539 2018-04-20
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
University of California, San Francisco
Phase 2 Completed
NCT00782756 2018-02-06
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00619112 2018-01-31
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT01736800 2017-09-19
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00086879 2017-07-27
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00638963 2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00076856 2017-05-09
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00883298 2017-03-30
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Center for Neurosciences, Tucson
Phase 2 Completed
NCT00436436 2017-03-28
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02898012 2016-09-13
ATAG
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00302159 2016-08-18
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01105702 2016-08-04
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
NYU Langone Health
Phase 2 Terminated
NCT02832635 2016-07-14
A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
Sun Yat-sen University
Phase 2 Unknown
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT00498927 2016-02-29
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00616005 2014-08-18
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Duke University
Phase 2 Completed
NCT00003466 2014-07-09
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00597402 2014-05-07
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
Phase 2 Completed
NCT00004204 2014-01-06
Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00575887 2013-12-20
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Marmara University
Phase 2 Completed
NCT00431561 2013-12-03
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Isarna Therapeutics GmbH
Phase 2 Completed
NCT00597493 2013-06-24
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Duke University
Phase 2 Completed
NCT00005954 2013-06-20
Temozolomide in Treating Patients With Brain Metastases
Duke University
Phase 2 Completed
NCT00004113 2013-06-19
Temozolomide in Treating Patients With Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005812 2013-05-14
Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT01015534 2013-05-08
Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment
Instituto Nacional de Cancerologia de Mexico
Phase 2 Completed
NCT00072163 2013-01-17
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00717275 2012-10-01
Study of Temozolomide to Treat Newly Diagnosed Brain Metastases
University of Florida
Phase 2 Terminated
NCT00238251 2012-06-05
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases
Swiss Cancer Institute
Phase 2 Completed
NCT01285414 2012-04-11
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme
Myrexis Inc.
Phase 2 Completed